Financial Comparison: Vaxart (OTCMKTS:VXRT) & Palisade Bio (NASDAQ:PALI)

Palisade Bio (NASDAQ:PALI) and Vaxart (OTCMKTS:VXRT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Palisade Bio and Vaxart, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1	0	7	2	3.00
Vaxart	0	1	0	0	2.00

Palisade Bio presently has a consensus price target of $9.00, suggesting a potential upside of 466.04%. Given Palisade Bio’s stronger consensus rating and higher possible upside, research analysts clearly believe Palisade Bio is more favorable than Vaxart.

Profitability

This table compares Palisade Bio and Vaxart’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-33.47%	-31.79%
Vaxart	15.88%	53.04%	20.85%

Risk & Volatility

Palisade Bio has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Valuation & Earnings

This table compares Palisade Bio and Vaxart”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$500,000.00	554.18	-$16.78 million	($0.48)	-3.31
Vaxart	$47.40 million	2.50	$16.33 million	$0.16	3.04

Vaxart has higher revenue and earnings than Palisade Bio. Palisade Bio is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

11.8% of Palisade Bio shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 0.1% of Palisade Bio shares are owned by company insiders. Comparatively, 2.8% of Vaxart shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Vaxart beats Palisade Bio on 9 of the 15 factors compared between the two stocks.

About Palisade Bio

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

About Vaxart

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.